{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:22:50Z","timestamp":1792106570567,"version":"4.4.0"},"reference-count":42,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Our objective was to evaluate the efficacy, durability, and tolerability of bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) in a real\u2010world setting in Belgium.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective, multicentre cohort study involving adult treatment\u2010na\u00efve (TN) and treatment\u2010experienced (TE) people living with HIV receiving BIC\/FTC\/TAF between 1 January 2019 and 30 September 2020. The primary outcome was rate of virological suppression (plasma HIV\u20101 viral load &lt;50 copies\/mL; on\u2010treatment analysis) at weeks 24 and 48. The main secondary outcomes included loss of virological suppression (LVS; two consecutive viral loads of &gt;200 copies\/mL after being virologically suppressed) by week 48 and analysis of resistance\u2010associated mutations at time of LVS; tolerability of BIC\/FTC\/TAF over the 48\u2010week study period; and change in weight and proportion of participants reporting a &gt;10% weight gain at week 48.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 2001 participants were included. Through 48\u2009weeks, overall rate of virological suppression was 93.5%, with similar results observed in the following subgroups: age \u226550\u2009years (92.7%), women (92.8%), Black sub\u2010Saharan African (91%), TN (94%), TE (93.2%), and non\u2010suppressed at baseline (86.6%). LVS was observed in 0.7% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200914) of participants, with one participant developing resistance\u2010associated mutations to nucleoside reverse transcriptase inhibitors (184\u2009V) and integrase strand transfer inhibitors (263KR). Of the 131 (6.5%) treatment discontinuations, the most common reason was an adverse event (2.4%), with the most frequent being central nervous system\/psychiatric (0.4%) and gastrointestinal (0.4%) toxicity. Median weight gain at week 48 was 2\u2009kg (interquartile range \u22121 to 5), and a &gt;10% weight increase was observed in 11.6% of participants.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this large real\u2010world cohort, BIC\/FTC\/TAF showed excellent virological efficacy in a diverse population of patients with HIV. Rare occurrence of emergent drug resistance was observed, and treatment was well tolerated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hiv.13493","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T23:45:47Z","timestamp":1681170347000},"page":"914-924","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Efficacy, durability, and tolerability of bictegravir\/emtricitabine\/tenofovir alafenamide for the treatment of\n                    <scp>HIV<\/scp>\n                    in a real\u2010world setting in Belgium"],"prefix":"10.1111","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1265-1500","authenticated-orcid":false,"given":"Rakan","family":"Nasreddine","sequence":"first","affiliation":[{"name":"Saint\u2010Pierre University Hospital  Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Florence","sequence":"additional","affiliation":[{"name":"Institute of Tropical Medicine  Antwerp Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Cyr","family":"Yombi","sequence":"additional","affiliation":[{"name":"Cliniques Universitaires Saint\u2010Luc  Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Henrard","sequence":"additional","affiliation":[{"name":"University Clinics of Brussels \u2013 Erasme Hospital  Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8192-1351","authenticated-orcid":false,"given":"Gilles","family":"Darcis","sequence":"additional","affiliation":[{"name":"Li\u00e8ge University Hospital  Li\u00e8ge Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7125-7001","authenticated-orcid":false,"given":"Jens","family":"Van Praet","sequence":"additional","affiliation":[{"name":"AZ Sint\u2010Jan Brugge\u2010Oostende  Brugge Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linos","family":"Vandekerckhove","sequence":"additional","affiliation":[{"name":"Ghent University Hospital  Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine D.","family":"Allard","sequence":"additional","affiliation":[{"name":"Universitair Ziekenhuis Brussel  Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9my","family":"Demeester","sequence":"additional","affiliation":[{"name":"University Hospital of Charleroi  Lodelinsart Charleroi Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Messiaen","sequence":"additional","affiliation":[{"name":"Jessa Hospital  Hasselt Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Ausselet","sequence":"additional","affiliation":[{"name":"UCL University Hospital Namur\u2010Godinne  Yvoir Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Delforge","sequence":"additional","affiliation":[{"name":"Saint\u2010Pierre University Hospital  Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"De Wit","sequence":"additional","affiliation":[{"name":"Saint\u2010Pierre University Hospital  Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Belgian Research on AIDS and HIV Consortium (BREACH)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,4,10]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"U.S. Department of Health and Human Services.Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Available at:https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/AdultandAdol escentGL.pdf. Accessed September 5 2022"},{"key":"e_1_2_9_3_1","unstructured":"European AIDS Clinical Society.European guidelines for clinical management and treatment of HIV\u20101\u2010infected adults in Europe version 11 2021. Available at:https:\/\/www.eacsociety.org\/media\/final2021eacsguidelinesv11.0_oct2021.pdf. Accessed September 5 2022"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17025"},{"key":"e_1_2_9_5_1","unstructured":"World Health Organization.Updated recommendations on first\u2010line and second\u2010line antiretroviral regimens and post\u2010exposure prophylaxis and recommendations on early infant diagnosis of HIV. HIV Treatment\u2010Interim Guidance 2018 Available at:http:\/\/apps.who.int\/iris\/bitstream\/handle\/ 10665\/273632\/WHO\u2010CDS\u2010HIV\u201018.18\u2010eng.pdf?ua=1. Accessed September 5 2022"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30016-4"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32299-7"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32340-1"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30080-3"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30077-3"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30092-4"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30091-2"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa988"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02605-12"},{"key":"e_1_2_9_15_1","unstructured":"Sciensano.Epid\u00e9miologie du sida et de l'infection \u00e0 VIH en Belgique: situation au 31 d\u00e9cembre 2020. Available at:https:\/\/www.sciensano.be\/en\/biblio\/epidemiologie-du-sida-et-de-linfection-a-vih-en-belgique-situation-au-31-decembre-2020. Accessed September 9 2022"},{"key":"e_1_2_9_16_1","unstructured":"United Nations Statistics Division.Composition of macro geographical (continental) regions geographical sub\u2010regions and selected economic other groupings. Available at:https:\/\/unstats.un.org\/unsd\/mi\/africa.htm. Accessed September 9 2022"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz347"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002454"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa439.419"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa439.1189"},{"key":"e_1_2_9_21_1","unstructured":"WohlDA PozniakA WorkowskiK et al.B\/F\/TAF five\u2010year outcomes in treatment\u2010naive adults. [Abstract 494] 29th Conference on Retroviruses and Opportunistic Infections (CROI) 12\u201316 February 2022."},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002137"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab481"},{"key":"e_1_2_9_24_1","unstructured":"Mic\u00e1nR deGeaGA BuscaC et al.Efficacy of switching to bictegravir\/emtricitabine\/tenofovir alafenamide in patients with pre\u2010existing NRTI resistances: Real world data. [Abstract 96] 18th European AIDS Conference (EACS) 27\u201330 October 2021."},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000027330"},{"key":"e_1_2_9_26_1","unstructured":"SpinnerCD StoehrA WongA et al.Starting or switching to bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) in clinical practice: Pooled 12\u2010month results from the global BICSTaR study. [Abstract 46] HIV Drug Therapy 5\u20138 October 2020."},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-020-03154-z"},{"key":"e_1_2_9_28_1","unstructured":"BraunP WiesmannF NaethG KnechtenH StollM.Development of integrase inhibitor resistance under firstline treatment with Bictegravir. [Abstract 125] HIV Drug Therapy 5\u20138 October 2022."},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab297"},{"key":"e_1_2_9_30_1","unstructured":"DaunyV GrasE LeviL et al.Identification of a treatment\u2010emergent integrase resistance mutation in an HIV late\u2010presenter on first\u2010line therapy. [Abstract 209] 18th European AIDS Conference (EACS) 27\u201330 October 2021."},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm516"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200110010-00001"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis104"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/2325958221996860"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002496"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz999"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000616"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.36469\/jheor.2021.2435"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000680"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-018-1227-0"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky145"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10163456"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ296"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.13493","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T20:59:16Z","timestamp":1692305956000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.13493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,10]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1111\/hiv.13493"],"URL":"https:\/\/doi.org\/10.1111\/hiv.13493","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,10]]},"assertion":[{"value":"2022-12-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}